Summarized by Masters of Longevity from Longevity Investors News.
Investor-focused coverage previewing a conference roundup on longevity biotech trends, investment patterns, and how to judge emerging aging claims.
Key Takeaways
- Longevity biotech moved from animal studies to human trials, exemplified by Life Biosciences dosing a first participant for an epigenetic eye therapy.
- Investment is concentrated: median 2026 longevity deals were $21.8M while the average was $91.2M, driven by a few large rounds.
- Validated aging biomarkers remain lacking, and projects analyzing trial blood samples aim to identify biomarkers that predict clinical outcomes.
